Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tax Benefits, Branded Portfolio, Synergies Drive Actavis’ Acquisition of Warner Chilcott

Executive Summary

Actavis’ purchase of Warner Chilcott will lower the former’s overall tax rate significantly, expand its specialty pharma business to 25% of total revenues, and provide global critical mass – all necessary responses to a future that includes fewer opportunities for small molecule generics and greater pricing pressures.

You may also be interested in...



How US Tax Plan Could Affect Global Pharma Manufacturing Networks

Allergan, Pfizer, Bristol-Myers Squibb, AbbVie, GSK, Sanofi and Roche showed glimpses in recent earnings calls of potential impacts on their global manufacturing networks from a US plan to legislate border-adjusted tax cuts. But there was not a word about President Trump’s threat of tariffs.

Biotech And Specialty Pharma’s M&A Power Gains On Big Pharma, EY Report

Big pharma continues to have the most buying power, according to EY’s annual M&A report, but the buying power of big biotech and specialty pharma grew significantly more.

Teva Loses 180-Day Exclusivity For Generic Actonel As FDA Stands Firm On Review Delays

Mylan’s product launches as FDA tells Teva that the agency’s delay in granting tentative ANDA approval does not prevent forfeiture of exclusivity.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS055360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel